Much of the premise for KIBRA as a tumor suppressor comes from its role in activating the Hippo pathway, for which loss of function and the concomitant activation of YAP/TAZ are well-documented in TNBCs (Cordenonsi et al., 2011). This evidence concerns the gene YAP1 and neoplasm.